KDM7A

Summary

KDM7A (lysine demethylase 7A, HGNC:22224) is a protein-coding gene on chromosome 7q34, encoding Lysine-specific demethylase 7A (Q6ZMT4). Histone demethylase required for brain development.

Enables histone demethylase activity and transition metal ion binding activity. Predicted to be involved in chromatin remodeling; midbrain development; and regulation of transcription by RNA polymerase II. Predicted to be located in nucleoplasm. Implicated in melanoma.

Source: NCBI Gene 80853 — automated summary from GO annotations (Alliance of Genome Resources).

At a glance

• Gene–disease (curated): cerebral palsy (Limited, GenCC)
• GWAS associations: 5
• Clinical variants (ClinVar): 92 total
• Regional missense constraint (gnomAD): 1 of 4 regions constrained (≈1% of expected missense variation)
• GTEx eGene: eQTL in 35 tissues, sQTL in 0 (q < 0.05)
• ChEMBL bioactivity: 1 clinical-phase molecule tested; no curated mechanism-of-action drug
• Constraint (gnomAD): pLI 1.00 (loss-of-function intolerant), LOEUF 0.41 (moderately constrained)
• MANE Select transcript: NM_030647
• Notable: 92 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:22224
Approved symbol	KDM7A
Name	lysine demethylase 7A
Location	7q34
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1718
Ensembl gene	ENSG00000006459
Ensembl biotype	protein_coding
OMIM	619640
Entrez	80853

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 6 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron

MANE Select: ENST00000397560

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 2

ENST00000397560, ENST00000472616, ENST00000478996, ENST00000895776, ENST00000912301, ENST00000942646, ENST00000997615, ENST00001110820, ENST00001136425

RefSeq mRNA: 1 — MANE Select: NM_030647 NM_030647

CCDS: CCDS43658

Canonical transcript exons

ENST00000397560 — 20 exons

Exon	Start	End
ENSE00000360316	140120442	140120529
ENSE00000726713	140096555	140096763
ENSE00000726716	140096899	140097047
ENSE00000726724	140097545	140097642
ENSE00000726740	140098879	140099033
ENSE00000726787	140111095	140111184
ENSE00000726816	140124621	140124783
ENSE00000726821	140126637	140126823
ENSE00000726824	140127442	140127583
ENSE00001155866	140099899	140100023
ENSE00001155872	140101951	140102160
ENSE00001155888	140119113	140119219
ENSE00001155914	140129493	140129653
ENSE00001155929	140084746	140091188
ENSE00001400748	140133539	140133656
ENSE00001401297	140139105	140139190
ENSE00001414149	140113491	140113582
ENSE00001890729	140176744	140176983
ENSE00003496538	140094056	140094138
ENSE00003509046	140091804	140092077

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 95.40.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.6782 / max 237.9970, expressed in 1656 samples.

Highest expression (Bgee): cartilage tissue, tendon of biceps brachii, gluteal muscle, bone marrow, upper leg skin.

Genetic regulation across tissues (GTEx eQTL / sQTL)

KDM7A is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 35 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 35 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Nerve Tibial	eqtl	5.2e-19	+0.45	7:140095480:A:G
Cells Cultured fibroblasts	eqtl	2.3e-12	+0.27	7:140200979:C:T
Brain Cerebellum	eqtl	6.1e-12	+0.63	7:140184390:G:T
Brain Caudate basal ganglia	eqtl	1.5e-11	+0.64	7:140091534:C:A
Brain Nucleus accumbens basal ganglia	eqtl	1.7e-11	+0.81	7:140085851:A:G
Brain Frontal Cortex BA9	eqtl	2.2e-11	+0.61	7:140091534:C:A
Brain Cerebellar Hemisphere	eqtl	5.9e-11	+0.42	7:140085851:A:G
Brain Cortex	eqtl	2.7e-10	+0.72	7:140091534:C:A
Brain Spinal cord cervical c-1	eqtl	3.2e-10	+0.78	7:140204606:A:T
Brain Putamen basal ganglia	eqtl	6.2e-09	+0.69	7:140169572:G:C
Brain Hippocampus	eqtl	2.7e-08	+0.59	7:140085851:A:G
Brain Substantia nigra	eqtl	1.3e-07	+0.70	7:140091534:C:A
Pancreas	eqtl	7.8e-07	+0.35	7:140181053:T:TAAGAA
Pituitary	eqtl	1.0e-05	+0.36	7:140181053:T:TAAGAA
Colon Sigmoid	eqtl	7.4e-05	+0.23	7:140185490:A:G
Whole Blood	eqtl	3.2e-04	-0.06	7:140305393:G:A
Muscle Skeletal	eqtl	4.1e-04	+0.08	7:140235772:C:A
Thyroid	eqtl	4.5e-04	+0.16	7:140169572:G:C
Spleen	eqtl	5.7e-04	+0.29	7:140091534:C:A
Cells EBV-transformed lymphocytes	eqtl	1.4e-03	-0.27	7:140211329:G:A

FANTOM5 promoters

4 alternative TSS:

Promoter ID	TPM avg	Samples expressed
86537	5.5326	1310
86536	3.1107	1018
86538	2.7010	1056
86533	0.3338	146

Top tissues by expression

showing 100 of 295 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cartilage tissue	UBERON:0002418	95.40	gold quality
tendon of biceps brachii	UBERON:0008188	94.67	gold quality
gluteal muscle	UBERON:0002000	93.76	gold quality
bone marrow	UBERON:0002371	91.74	gold quality
upper leg skin	UBERON:0004262	91.72	gold quality
epithelium of nasopharynx	UBERON:0001951	91.66	gold quality
monocyte	CL:0000576	91.08	gold quality
mononuclear cell	CL:0000842	91.06	gold quality
leukocyte	CL:0000738	90.63	gold quality
cervix squamous epithelium	UBERON:0006922	90.17	silver quality
buccal mucosa cell	CL:0002336	90.10	gold quality
skin of hip	UBERON:0001554	89.57	gold quality
bone marrow cell	CL:0002092	89.47	gold quality
jejunal mucosa	UBERON:0000399	89.36	gold quality
trabecular bone tissue	UBERON:0002483	88.94	gold quality
squamous epithelium	UBERON:0006914	88.36	gold quality
gastrocnemius	UBERON:0001388	88.25	gold quality
blood	UBERON:0000178	88.16	gold quality
esophagus squamous epithelium	UBERON:0006920	88.08	gold quality
jejunum	UBERON:0002115	88.05	gold quality
pharyngeal mucosa	UBERON:0000355	87.86	gold quality
tendon	UBERON:0000043	87.65	gold quality
mucosa of sigmoid colon	UBERON:0004993	87.31	gold quality
sperm	CL:0000019	87.30	silver quality
muscle of leg	UBERON:0001383	87.02	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	87.02	gold quality
gingival epithelium	UBERON:0001949	86.98	gold quality
colonic epithelium	UBERON:0000397	86.84	gold quality
colonic mucosa	UBERON:0000317	86.79	gold quality
pericardium	UBERON:0002407	86.73	gold quality
skin of leg	UBERON:0001511	86.46	gold quality
tonsil	UBERON:0002372	86.29	gold quality
medial globus pallidus	UBERON:0002477	86.09	gold quality
zone of skin	UBERON:0000014	86.03	gold quality
oviduct epithelium	UBERON:0004804	85.99	gold quality
gingiva	UBERON:0001828	85.92	gold quality
skin of abdomen	UBERON:0001416	85.74	gold quality
epithelium of esophagus	UBERON:0001976	85.73	gold quality
bronchus	UBERON:0002185	85.71	gold quality
bronchial epithelial cell	CL:0002328	85.70	gold quality
epithelium of bronchus	UBERON:0002031	85.70	gold quality
duodenum	UBERON:0002114	85.61	gold quality
rectum	UBERON:0001052	85.49	gold quality
cervix epithelium	UBERON:0004801	85.47	gold quality
muscle organ	UBERON:0001630	85.21	gold quality
male germ cell	CL:0000015	85.09	silver quality
body of tongue	UBERON:0011876	84.93	gold quality
subcutaneous adipose tissue	UBERON:0002190	84.81	gold quality
placenta	UBERON:0001987	84.78	gold quality
tongue	UBERON:0001723	84.67	gold quality
biceps brachii	UBERON:0001507	84.58	gold quality
secondary oocyte	CL:0000655	84.57	gold quality
saphenous vein	UBERON:0007318	84.47	gold quality
calcaneal tendon	UBERON:0003701	84.45	gold quality
deltoid	UBERON:0001476	84.25	silver quality
urethra	UBERON:0000057	84.18	gold quality
diaphragm	UBERON:0001103	84.15	gold quality
mucosa of paranasal sinus	UBERON:0005030	83.99	gold quality
choroid plexus epithelium	UBERON:0003911	83.97	gold quality
nasal cavity mucosa	UBERON:0001826	83.96	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	83.96	gold quality
uterine cervix	UBERON:0000002	83.85	gold quality
endothelial cell	CL:0000115	83.81	gold quality
nasal cavity epithelium	UBERON:0005384	83.81	gold quality
mucosa of stomach	UBERON:0001199	83.71	gold quality
right lung	UBERON:0002167	83.63	gold quality
synovial joint	UBERON:0002217	83.63	gold quality
superior surface of tongue	UBERON:0007371	83.63	gold quality
globus pallidus	UBERON:0001875	83.31	gold quality
triceps brachii	UBERON:0001509	83.18	gold quality
caecum	UBERON:0001153	83.16	gold quality
epithelium of mammary gland	UBERON:0003244	83.15	gold quality
connective tissue	UBERON:0002384	83.13	gold quality
thoracic mammary gland	UBERON:0005200	83.07	gold quality
mammary gland	UBERON:0001911	83.05	gold quality
vermiform appendix	UBERON:0001154	82.89	gold quality
adipose tissue	UBERON:0001013	82.82	gold quality
minor salivary gland	UBERON:0001830	82.81	gold quality
transverse colon	UBERON:0001157	82.77	gold quality
mucosa of urinary bladder	UBERON:0001259	82.73	gold quality
esophagus mucosa	UBERON:0002469	82.70	gold quality
mouth mucosa	UBERON:0003729	82.70	gold quality
vena cava	UBERON:0004087	82.66	gold quality
large intestine	UBERON:0000059	82.61	gold quality
endometrium	UBERON:0001295	82.59	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	82.57	gold quality
pylorus	UBERON:0001166	82.52	gold quality
mammary duct	UBERON:0001765	82.49	gold quality
intestine	UBERON:0000160	82.44	gold quality
hindlimb stylopod muscle	UBERON:0004252	82.39	gold quality
colon	UBERON:0001155	82.38	gold quality
tibialis anterior	UBERON:0001385	82.22	gold quality
nipple	UBERON:0002030	82.11	gold quality
small intestine	UBERON:0002108	82.06	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.01	gold quality
cauda epididymis	UBERON:0004360	81.99	gold quality
lower lobe of lung	UBERON:0008949	81.86	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	81.84	gold quality
granulocyte	CL:0000094	81.82	gold quality
lower esophagus mucosa	UBERON:0035834	81.78	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-CURD-10	no	478.17
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 79 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Cerebral cortex	tissue	29.9	high
Occipital cortex	tissue	29.9
Somatosensory cortex	tissue	28.8
Superior colliculi	tissue	26.6
Olfactory bulb	tissue	25.5
Thalamus	tissue	24.8
Motor cortex	tissue	21.4
Midbrain	tissue	20.8
Hippocampal formation	tissue	20.2
Entorhinal cortex	tissue	20.2
Retrosplenial and cingulate cortex	tissue	19.7
Pons	tissue	19.5
Spinal cord	tissue	19.3
Temporal cortex	tissue	19.3
Prefrontal cortex	tissue	19.0
Putamen	tissue	19.0
Cerebellum	tissue	18.9	medium
Retrosplenial cortex	tissue	18.4
Insular cortex	tissue	16.7
Medulla oblongata	tissue	16.2
Substantia nigra	tissue	16.1
Corpus callosum	tissue	15.8
Bone marrow	tissue	15.5	high
Basal ganglia	tissue	14.9	medium
Ventral forebrain	tissue	14.9
Caudate putamen	tissue	14.0
Periaqueductal gray	tissue	13.3
Hypothalamus	tissue	12.7
Amygdala	tissue	12.6
Tongue	tissue	12.3
Septum	tissue	12.3
Frontal cortex	tissue	11.0
Cervix	tissue	9.0	high
Stomach 1	tissue	8.8	low
Rectum	tissue	8.8	high
Placenta	tissue	8.6	high
Colon	tissue	7.9	high
Small intestine	tissue	7.8	high
Duodenum	tissue	7.7	high
Tonsil	tissue	7.5	high
Hippocampus	tissue	7.4	high
Postcentral gyrus	tissue	7.3
Testis	tissue	7.2	low
Choroid plexus	tissue	6.7
Lymph node	tissue	6.5	low
Esophagus	tissue	6.5	high
Appendix	tissue	6.5	high
Endometrium 1	tissue	6.2	low
Liver	tissue	6.2	high
Thymus	tissue	6.2
Adipose tissue	tissue	6.1	low
Locus coeruleus	tissue	6.0
Retina	tissue	5.4
Urinary bladder	tissue	5.4	high
Nucleus accumbens	tissue	5.4
Spleen	tissue	5.3	medium
Lung	tissue	4.5	medium
Skin 1	tissue	4.3	high
Gallbladder	tissue	4.3	high
Pancreas	tissue	4.2	medium

Brain sub-regions (HPA Brain Atlas): detected in 191; highest nTPM — Ventral spinal cord (19.3), Dorsal hippocampus (19.1), Dorsal spinal cord (17.2), White matter (15.8), Ventral hippocampus (15.3).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): EPAS1, HIF1A

miRNA regulators (miRDB)

Targeting KDM7A by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 480 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-188-3P	100.00	68.76	1240

Functional genomics

gnomAD constraint: pLI 1, LOEUF 0.405, missense Z 1.11 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000397560 splits into 4 regions with different missense tolerance; 1 is missense-constrained (≈1% of the expected missense variation). Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
7:140,091,097–140,111,155	512 / 576.6	0.89	no
7:140,111,156–140,113,504	0 / 16.6	0.00	yes (p 4.6e-05)
7:140,113,505–140,176,751	318 / 453.1	0.70	no
7:140,176,752–140,176,937	112 / 96.2	1.16	no

Literature-anchored findings (GeneRIF, showing 13)

• KIAA1718 is a dual-specificity histone demethylase that regulates neural differentiation through FGF4. (PMID:20084082)
• increased JHDM1D expression suppresses tumor growth by down-regulating angiogenesis under nutrient starvation (PMID:22143793)
• Histone modifier genes (JMJD1C, RREB1, MINA, KDM7A) alter conotruncal heart phenotypes in 22q11.2 deletion syndrome. (PMID:26608785)
• G9a promotes H3K27 methylation of the E-cadherin promoter by upregulating PCL3 to increase PRC2 promoter recruitment and by downregulating the H3K27 demethylase KDM7A to silence E-cadherin gene (PMID:26688070)
• KDM7A mediates TNF-alpha-induced ICAM1 protein upregulation. (PMID:27565733)
• decreased expression in placenta associated with pre-eclampsia through down-regulating HLA-G (PMID:29662139)
• KDM7A is potentially a good therapeutic target for prostate cancer drugs. (PMID:30183076)
• Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer. (PMID:31236965)
• Coordinated demethylation of H3K9 and H3K27 is required for rapid inflammatory responses of endothelial cells. (PMID:32125007)
• Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells. (PMID:32781788)
• The nuclear bodies formed by histone demethylase KDM7A. (PMID:32935279)
• JHDM1D-AS1 aggravates the development of gastric cancer through miR-450a-2-3p-PRAF2 axis. (PMID:33245963)
• Inhibition of KDM2/7 Promotes Notochordal Differentiation of hiPSCs. (PMID:39273051)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	kdm7aa	ENSDARG00000018111
danio_rerio	kdm7ab	ENSDARG00000018559
mus_musculus	Kdm7a	ENSMUSG00000042599
rattus_norvegicus	Kdm7a	ENSRNOG00000052445
caenorhabditis_elegans		WBGENE00005013
caenorhabditis_elegans		WBGENE00017920

Paralogs (4): KDM2B (ENSG00000089094), PHF8 (ENSG00000172943), KDM2A (ENSG00000173120), PHF2 (ENSG00000197724)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:2443388) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 21 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal trabecular bone morphology	1
abnormal hair follicle morphology	1
abnormal sebaceous gland morphology	1
abnormal tail morphology	1
vertebral transformation	1
decreased osteoclast cell number	1
increased osteoblast cell number	1
decreased bone resorption	1
abnormal osteoclast differentiation	1
abnormal hair follicle bulge morphology	1
increased bone mineral content	1
increased bone trabecula number	1
increased trabecular bone mass	1
increased trabecular bone volume	1
abnormal fat cell differentiation	1
enhanced osteoblast differentiation	1
decreased bone trabecular spacing	1
increased bone ossification	1
increased bone mineralization	1
decreased tumor necrosis factor (ligand) superfamily member 11 level	1
decreased bone marrow adipose tissue amount	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Oryza sativa Indica Group	A2Y0Q2	100.0%	Diamond
Oryza sativa Japonica Group	Q6Z7F4	100.0%	Diamond
Cryptococcus deneoformans JEC21	P0CO40	97.4%	Diamond
Cryptococcus deneoformans B-3501A	P0CO41	97.4%	Diamond
Bos taurus	Q5EA28	95.3%	Diamond
Arabidopsis thaliana	Q9FFF5	86.8%	Diamond
Medicago sativa	Q40359	79.2%	Diamond
Dicentrarchus labrax	E6ZGB4	78.2%	Diamond
Xenopus laevis	Q640I9	73.8%	Diamond
Xenopus tropicalis	Q08D35	69.2%	Diamond
Caenorhabditis briggsae	Q60V67	66.8%	Diamond
Aspergillus nidulans FGSC A4	Q5AW75	64.6%	Diamond
Aspergillus fumigatus Af293	Q4WHB7	64.5%	Diamond
Drosophila melanogaster	Q9W0T1	60.8%	Diamond
Schizosaccharomyces pombe 972h-	O74508	53.1%	Diamond
Nakaseomyces glabratus CBS 138	Q6FPL6	52.2%	Diamond
Candida albicans SC5314	Q5A847	50.2%	Diamond
Debaryomyces hansenii CBS767	Q6BXJ4	50.2%	Diamond
Kluyveromyces lactis NRRL Y-1140	Q6CIC9	49.9%	Diamond
Yarrowia lipolytica CLIB122	Q6C423	43.0%	Diamond
Mycosarcoma maydis	Q4P5U1	42.0%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
KDM7A-DT	ncRNA	100134229
PARP12	protein-coding	64761
TBXAS1	protein-coding	6916

Protein

Protein identifiers

Lysine-specific demethylase 7A — Q6ZMT4 (reviewed: Q6ZMT4)

Alternative names: JmjC domain-containing histone demethylation protein 1D, Lysine-specific demethylase 7, [histone H3]-dimethyl-L-lysine9 demethylase 7A

All UniProt accessions (2): Q6ZMT4, H9KVD6

UniProt curated annotations — full annotation on UniProt →

Function. Histone demethylase required for brain development. Specifically demethylates dimethylated ‘Lys-9’, ‘Lys-27’ and ‘Lys-36’ (H3K9me2, H3K27me2, H3K36me2, respectively) of histone H3 and monomethylated histone H4 ‘Lys-20’ residue (H4K20Me1), thereby playing a central role in histone code. Specifically binds trimethylated ‘Lys-4’ of histone H3 (H3K4me3), affecting histone demethylase specificity: in presence of H3K4me3, it has no demethylase activity toward H3K9me2, while it has high activity toward H3K27me2. Demethylates H3K9me2 in absence of H3K4me3. Has activity toward H4K20Me1 only when nucleosome is used as a substrate and when not histone octamer is used as substrate.

Subcellular location. Nucleus.

Cofactor. Binds 1 Fe(2+) ion per subunit.

Domain organisation. The PHD-type zinc finger mediates the binding to H3K4me3. Binding to H3K4me3 prevents its access to H3K9me2. The linker region is a critical determinant of demethylase specificity. It prevents the active site of JmjC to reach the target H3K9me2 when the PHD-type zinc finger binds to H3K4me3, while it favors selectivity toward H3K27me2.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the JHDM1 histone demethylase family. JHDM1D subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6ZMT4-1	1	yes
Q6ZMT4-2	2

RefSeq proteins (1): NP_085150* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001965	Znf_PHD	Domain
IPR003347	JmjC_dom	Domain
IPR011011	Znf_FYVE_PHD	Homologous_superfamily
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR019786	Zinc_finger_PHD-type_CS	Conserved_site
IPR019787	Znf_PHD-finger	Domain
IPR041070	JHD	Domain
IPR050690	JHDM1_Histone_Demethylase	Family

Pfam: PF00628, PF02373, PF17811

Enzyme classification (BRENDA)

• EC 1.14.11.65 — [histone H3]-dimethyl-L-lysine9 demethylase (BRENDA: 9 organisms, 67 substrates, 84 inhibitors, 4 Km, 4 kcat entries)

Substrate kinetics (BRENDA)

2 substrates with measured Km, best-characterized 2. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
[HISTONE H3]-N6,N6-DIMETHYL-L-LYSINE9	0.106–0.1061	2
[HISTONE H3]-N6-METHYL-L-LYSINE9	0.095–0.0952	2

Catalyzed reactions (Rhea)

• N(6),N(6)-dimethyl-L-lysyl(36)-[histone H3] + 2-oxoglutarate + O2 = N(6)-methyl-L-lysyl(36)-[histone H3] + formaldehyde + succinate + CO2 (RHEA:21788)
• N(6),N(6)-dimethyl-L-lysyl(9)-[histone H3] + 2 2-oxoglutarate + 2 O2 = L-lysyl(9)-[histone H3] + 2 formaldehyde + 2 succinate + 2 CO2 (RHEA:60188)
• N(6),N(6)-dimethyl-L-lysyl(27)-[histone H3] + 2 2-oxoglutarate + 2 O2 = L-lysyl(27)-[histone H3] + 2 formaldehyde + 2 succinate + 2 CO2 (RHEA:67800)
• N(6)-methyl-L-lysyl(20)-[histone H4] + 2-oxoglutarate + O2 = L-lysyl(20)-[histone H4] + formaldehyde + succinate + CO2 (RHEA:67804)

UniProt features (72 total): helix 27, strand 17, turn 8, binding site 5, region of interest 4, compositionally biased region 3, splice variant 2, chain 1, domain 1, modified residue 1, sequence variant 1, sequence conflict 1, zinc finger region 1

Structure

Experimental structures (PDB)

6 structures by resolution:

PDB	Title	Method	Resolution (Å)
3KV9	Structure of KIAA1718 Jumonji domain	X-RAY DIFFRACTION	2.29
3KV5	Structure of KIAA1718, human Jumonji demethylase, in complex with N-oxalylglycine	X-RAY DIFFRACTION	2.39
3U78	E67-2 selectively inhibits KIAA1718, a human histone H3 lysine 9 Jumonji demethylase	X-RAY DIFFRACTION	2.69
3KVB	Structure of KIAA1718 Jumonji domain in complex with N-oxalylglycine	X-RAY DIFFRACTION	2.69
3KVA	Structure of KIAA1718 Jumonji domain in complex with alpha-ketoglutarate	X-RAY DIFFRACTION	2.79
3KV6	Structure of KIAA1718, human Jumonji demethylase, in complex with alpha-ketoglutarate	X-RAY DIFFRACTION	2.89

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6ZMT4-F1	66.80	0.47

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Oxidoreductases, Predicted intracellular proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nucleoplasm; nucleoli

Antibody reliability (HPA): IH uncertain · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (5)

Position	Role
279	substrate
282	Fe cation
284	Fe cation
299	substrate
354	Fe cation

Post-translational modifications (1)

Type	Positions
Phosphoserine	604

Function

Pathways and Gene Ontology

Reactome pathways

2 curated (TAS) of 7; 4 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

7 pathways:

ID	Pathway	Evidence
R-HSA-6802952	Signaling by BRAF and RAF1 fusions ⚕	curated
R-HSA-3214842	HDMs demethylate histones	curated
R-HSA-1643685	Disease ⚕	—
R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers ⚕	—
R-HSA-6802957	Oncogenic MAPK signaling ⚕	—
R-HSA-3247509	Chromatin modifying enzymes	—
R-HSA-4839726	Chromatin organization	—

MSigDB gene sets: 329 (showing top): GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, PEREZ_TP63_TARGETS, IVANOVA_HEMATOPOIESIS_MATURE_CELL, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP, BILD_HRAS_ONCOGENIC_SIGNATURE, ONKEN_UVEAL_MELANOMA_UP, MODULE_256, GOBP_MIDBRAIN_DEVELOPMENT, MODULE_206, GOBP_HEAD_DEVELOPMENT, CUI_TCF21_TARGETS_2_DN, MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP, GOBP_CHROMATIN_REMODELING, CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP, GOCC_NUCLEOLUS

GO Biological Process (7): chromatin remodeling (GO:0006338), DNA-templated transcription (GO:0006351), regulation of transcription by RNA polymerase II (GO:0006357), midbrain development (GO:0030901), positive regulation of DNA-templated transcription (GO:0045893), chromatin organization (GO:0006325), nervous system development (GO:0007399)

GO Molecular Function (13): transcription coregulator activity (GO:0003712), iron ion binding (GO:0005506), zinc ion binding (GO:0008270), 2-oxoglutarate-dependent dioxygenase activity (GO:0016706), histone demethylase activity (GO:0032452), histone H3K9 demethylase activity (GO:0032454), histone H4K20 demethylase activity (GO:0035575), histone H3K36 demethylase activity (GO:0051864), histone H3K27me2/H3K27me3 demethylase activity (GO:0071558), histone H3K9me/H3K9me2 demethylase activity (GO:0140683), oxidoreductase activity (GO:0016491), metal ion binding (GO:0046872), dioxygenase activity (GO:0051213)

GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730)

Reactome top-level categories

5 top-level categories:

Category	Pathways
Chromatin modifying enzymes	1
Oncogenic MAPK signaling	1
Chromatin organization	1
Disease	1
Diseases of signal transduction by growth factor receptors and second messengers	1

GO top-level categories

28 GO namespaces:

Category	Terms
2-oxoglutarate-dependent dioxygenase activity	4
histone H3 demethylase activity	3
regulation of DNA-templated transcription	2
animal gross anatomical part developmental process	2
transition metal ion binding	2
nuclear lumen	2
chromatin organization	1
gene expression	1
RNA biosynthetic process	1
transcription by RNA polymerase II	1
brain development	1
DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
cellular component organization	1
system development	1
transcription regulator activity	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	1
dioxygenase activity	1
protein demethylase activity	1
histone modifying activity	1
histone H4 demethylase activity	1
histone H3K9 demethylase activity	1
catalytic activity	1
cation binding	1
oxidoreductase activity	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1
intracellular membraneless organelle	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 8 of 23 annotations. The rest are phylogenetic / computational / electronic (IEA).

8 experimentally-supported GO terms:

GO term	NS	Evidence
2-oxoglutarate-dependent dioxygenase activity	MF	direct assay
histone H3K27me2/H3K27me3 demethylase activity	MF	direct assay
histone H3K36 demethylase activity	MF	direct assay
histone H3K9 demethylase activity	MF	direct assay
histone H3K9me/H3K9me2 demethylase activity	MF	direct assay
histone H4K20 demethylase activity	MF	direct assay
iron ion binding	MF	direct assay
zinc ion binding	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 731 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KDM7A	KDM4A	O75164	679
KDM7A	KDM6B	O15054	642
KDM7A	KDM5A	P29375	618
KDM7A	JMJD1C	Q15652	614
KDM7A	KDM6A	O15550	610
KDM7A	KDM4C	Q9H3R0	602
KDM7A	KDM3A	Q9Y4C1	602
KDM7A	KDM4B	O94953	601
KDM7A	KDM5B	Q9UGL1	598
KDM7A	KDM3B	Q7LBC6	597
KDM7A	KDM4D	Q6B0I6	582
KDM7A	KDM1A	O60341	565
KDM7A	KDM5C	P41229	555
KDM7A	KDM8	Q8N371	533
KDM7A	Q08EI0	Q08EI0	523

IntAct

BioGRID (9 interactions; top human partners by supporting records): KDM6B (Affinity Capture-MS; 2 records), ACOT7 (Affinity Capture-MS), BCL6 (Affinity Capture-MS), JOSD2 (Affinity Capture-MS), KIAA1429 (Affinity Capture-RNA), NUDT21 (Affinity Capture-RNA), PARP1 (Proximity Label-MS), PARP11 (Proximity Label-MS)

SIGNOR signaling

3 signaling interactions:

A	Effect	B	Mechanism
HIF1A	“up-regulates quantity by expression”	KDM7A	“transcriptional regulation”
EPAS1	“up-regulates quantity by expression”	KDM7A	“transcriptional regulation”
2-oxoglutarate(2-)	“up-regulates activity”	KDM7A	“chemical activation”

Disease & clinical

Genetic variants

Variant evidence for KDM7A: 92 ClinVar records (0 pathogenic / likely pathogenic); 5 GWAS associations.

ClinVar

92 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	91
Likely benign	1
Benign	0

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 25 predictions of 2,301):

Position(s)	Effect	Δscore	Sites
7:140094054–140094055	donor_loss	1.0000	5
7:140094139–140094140	acceptor_loss	1.0000	4
7:140098877–140098878	donor_loss	1.0000	2
7:140099034–140099036	acceptor_gain	1.0000	3
7:140099034–140099035	acceptor_loss	1.0000	2
7:140099039	acceptor_gain	1.0000
7:140099902	donor_gain	1.0000
7:140101989	donor_gain	1.0000
7:140111093–140111094	donor_loss	1.0000	5
7:140111191	acceptor_gain	1.0000

AlphaMissense

2,207 missense substitutions predicted likely pathogenic (of 6,246 scored), across 475 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M52	9	0.986	0.999
M918	9	0.930	0.996
M738	9	0.893	0.993
M272	9	0.860	0.997
M384	9	0.839	0.995
H282	8	0.999	1.000
D284	8	0.999	1.000
D280	8	0.998	1.000
H63	8	0.997	0.999
F285	8	0.996	1.000
N368	8	0.996	1.000
H354	8	0.995	0.999
S227	8	0.993	1.000
F394	8	0.993	1.000
F51	8	0.990	1.000
D196	8	0.990	0.998
F230	8	0.988	1.000
F301	8	0.988	0.999
F281	8	0.987	0.999
H371	8	0.987	0.997

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

3 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	1.44e-05
Kidney Renal Clear Cell Carcinoma (validation)	favorable	0.000151
Lung Squamous Cell Carcinoma (validation)	favorable	0.000271

Disease associations

OMIM: gene MIM:619640 | disease phenotypes:

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
cerebral palsy	Limited	Autosomal dominant

Mondo (1): cerebral palsy (MONDO:0006497)

GWAS associations

5 associations:

Study	Trait	p-value
GCST90002400_230	Plateletcrit	8e-22
GCST90002402_383	Platelet count	9e-14
GCST90002402_384	Platelet count	4e-11
GCST004607_154	Plateletcrit	1e-9
GCST90002400_231	Plateletcrit	3e-9

EFO canonical traits (from GWAS)

2 canonical traits:

EFO ID	Trait name
EFO:0007985	platelet crit
EFO:0004309	platelet count

MeSH disease descriptors

1 disease descriptors:

Descriptor	Name	Tree numbers
D002547	Cerebral Palsy	C10.228.140.140.254

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2163177 (SINGLE PROTEIN), CHEMBL3038496 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 30,023 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

1 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL633	AMIODARONE	4	30,023

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Histone demethylases

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
daminozide	Inhibition	5.68	pIC50

Binding affinities (BindingDB)

15 measured of 16 human assays (16 total across all organisms); most potent 15 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
(2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine	KI	25 nM
CHEMBL4126235	IC50	1700 nM
CHEMBL4130224	IC50	120000 nM
CHEMBL4126406	IC50	126000 nM
CHEMBL4127515	IC50	221000 nM
CHEMBL4129980	IC50	240000 nM
CHEMBL4129830	IC50	242000 nM
CHEMBL4128613	IC50	286000 nM
WAG-003	IC50	307000 nM
CHEMBL4127792	IC50	377000 nM
CHEMBL4126135	IC50	386000 nM
WAG-005	IC50	390000 nM
CHEMBL4126951	IC50	397000 nM
CHEMBL4127094	IC50	496000 nM
CHEMBL4128152	IC50	697000 nM

ChEMBL bioactivities

6 potent at pChembl≥5 of 15 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.72	IC50	190	nM	CHEMBL5723343
6.70	IC50	200	nM	CHEMBL2424812
5.80	IC50	1600	nM	CHEMBL1229308
5.72	IC50	1900	nM	CHEMBL4126235
5.68	IC50	2100	nM	CHEMBL2164243
5.25	IC50	5600	nM	CHEMBL4126406

PubChem BioAssay actives

5 with measured affinity, of 38 total; 5 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-[9-cyclopropylnonanoyl(hydroxy)amino]propanoic acid	770453: Inhibition of KDM7A (unknown origin) using K27me2 peptide as substrate by MALDI assay	ic50	0.2000	uM
3-[9-(dimethylamino)nonanoyl-hydroxyamino]propanoic acid	770453: Inhibition of KDM7A (unknown origin) using K27me2 peptide as substrate by MALDI assay	ic50	1.6000	uM
[(5S)-6-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S,3R)-1-[[2-[[2-[[(2S)-6-amino-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]amino]-6-oxohexyl]-trimethylazanium	1496240: Displacement of C-terminally biotinylated-H3K4me3 (1 to 21 residues) peptide from KDM7A (PHD) (unknown origin) preincubated for 15 mins followed by peptide addition measured after 1 hr by luminescence-based AlphaScreen assay	ic50	1.9000	uM
4-(2,2-dimethylhydrazinyl)-4-oxobutanoic acid	698699: Inhibition of human KDM7A catalytic domain expressed in Escherichia coli by MALDI assay	ic50	2.1000	uM
trimethyl-[3-[4-(2-methyl-1-benzofuran-3-carbonyl)phenoxy]propyl]azanium iodide	1496244: Displacement of C-terminally biotinylated-H3K4me3 (1 to 21 residues) peptide from KDM7A (PHD-JmjC) (unknown origin) preincubated for 15 mins followed by peptide addition measured after 1 hr by luminescence-based AlphaScreen assay	ic50	5.6000	uM

CTD chemical–gene interactions

66 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, increases methylation	3
Cyclosporine	increases expression	3
sodium arsenite	decreases expression, increases expression	2
didecyldimethylammonium	increases expression	2
(+)-JQ1 compound	increases expression	2
Acetaminophen	increases expression	2
Benzo(a)pyrene	decreases expression	2
Folic Acid	affects cotreatment, increases expression	2
Nickel	increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
Cadmium Chloride	increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
FR900359	increases phosphorylation	1
TAK-243	increases sumoylation	1
sotorasib	affects cotreatment, decreases expression	1
alpha phellandrene	increases expression	1
bisphenol A	decreases methylation	1
arsenite	affects binding, decreases reaction	1
mono-(2-ethylhexyl)phthalate	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
nickel chloride	increases expression	1
benzo(e)pyrene	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluoro-n-nonanoic acid	increases expression	1
entinostat	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1

ChEMBL screening assays

10 unique, capped per target: 9 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2167521	Binding	Inhibition of human KDM7A catalytic domain expressed in Escherichia coli by MALDI assay	Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. — *J Med Chem*
CHEMBL5723316	Functional	Affinity Biochemical interaction: (AlphaScreen) EUB0002790a JHDM1D	Affinity Biochemical Literature for EUbOPEN Chemogenomic Library

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1G6	Abcam A-549 KDM7A KO 2	Cancer cell line	Male
CVCL_B2NP	Abcam A-549 KDM7A KO 1	Cancer cell line	Male
CVCL_SU53	HAP1 KDM7A (-) 1	Cancer cell line	Male
CVCL_SU54	HAP1 KDM7A (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00154830	Phase 4	COMPLETED	Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children
NCT00432055	Phase 4	COMPLETED	Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy
NCT00549471	Phase 4	TERMINATED	Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy
NCT00752934	Phase 4	TERMINATED	Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes?
NCT00964639	Phase 4	COMPLETED	Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies
NCT01386255	Phase 4	WITHDRAWN	Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy
NCT02546999	Phase 4	COMPLETED	Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?
NCT02633241	Phase 4	COMPLETED	A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging
NCT03117322	Phase 4	COMPLETED	Synbiotic, Prebiotics and Probiotics in Children With Cerebral Palsy and Constipation
NCT03648658	Phase 4	UNKNOWN	Paracetamol Study in Patients With Low Muscle Mass
NCT04074265	Phase 4	COMPLETED	Peri-operative Use of a Pain Injection in Pediatric Patients With Cerebral Palsy
NCT04273737	Phase 4	TERMINATED	Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy
NCT04523935	Phase 4	COMPLETED	Excessive Crying in Children With Cerebral Palsy and Communication Deficits
NCT05887765	Phase 4	COMPLETED	Effect of Systematic Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Pediatric Ankle Surgery
NCT06176430	Phase 4	UNKNOWN	Comparison of Twice Weekly Versus Daily Iron Therapy in Treating Anemia in Children With Cerebral Palsy
NCT06189781	Phase 4	RECRUITING	Pain Injection Versus Epidural Anesthesia for Hip Surgery in Pediatric Patients With Cerebral Palsy
NCT00014989	Phase 3	COMPLETED	Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)
NCT00065949	Phase 3	UNKNOWN	Magnesium Sulfate to Prevent Brain Injury in Premature Infants
NCT00367068	Phase 3	COMPLETED	Dutch National ITB Study in Children With Cerebral Palsy
NCT00491894	Phase 3	COMPLETED	Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions
NCT00632528	Phase 3	COMPLETED	MEOPA to Improve Physical Therapy Results After Multilevel Surgery
NCT00822029	Phase 3	TERMINATED	Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-walking Children With Cerebral Palsy
NCT00922077	Phase 3	COMPLETED	Individualized Neurodevelopmental Treatment
NCT01249417	Phase 3	COMPLETED	Dysport® Pediatric Lower Limb Spasticity Study
NCT01251380	Phase 3	COMPLETED	Dysport® Pediatric Lower Limb Spasticity Follow-on Study
NCT01437644	Phase 3	COMPLETED	The Post-Operative Pain in Cerebral Palsy (POPPIES) Trial
NCT01492608	Phase 3	COMPLETED	Magnesium Sulphate for Preterm Birth (MASP Study)
NCT01603602	Phase 3	COMPLETED	BOTOX® Treatment in Pediatric Upper Limb Spasticity
NCT01603615	Phase 3	COMPLETED	BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
NCT01603628	Phase 3	COMPLETED	BOTOX® Treatment in Pediatric Lower Limb Spasticity
NCT01603641	Phase 3	COMPLETED	BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity
NCT01633736	Phase 3	UNKNOWN	Targeted Hip Strength Training in Children With Cerebral Palsy (CP)
NCT01898520	Phase 3	COMPLETED	A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years
NCT01929434	Phase 3	COMPLETED	Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Patients With Cerebral Paralysis
NCT02002884	Phase 3	COMPLETED	Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
NCT02270736	Phase 3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02839785	Phase 3	TERMINATED	Analgesia and Physiotherapy in Children With Cerebral Palsy (ANTALKINECP)
NCT03110341	Phase 3	UNKNOWN	Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome
NCT03302871	Phase 3	COMPLETED	Integrated Management Enhances Functional Gains in Children With Cerebral Palsy Treated by BoNT-A
NCT03306212	Phase 3	COMPLETED	Efficacy of Intermittent Serial Casting on Spastic Wrist Flexion Deformity
NCT03469999	Phase 3	COMPLETED	Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy
NCT03472261	Phase 3	COMPLETED	Integrated Management of Pronation Deformity in Cerebral Palsy
NCT03616067	Phase 3	TERMINATED	Evaluation of the Efficacy of the Injection of Botulinum Toxin A vs Scopolamine Patches in the Treatment of Drooling in Children With Cerebral Palsy
NCT05206513	Phase 3	COMPLETED	Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
NCT06128616	Phase 3	UNKNOWN	Efficacy of Extracorporeal Shock Wave Therapy in Children With Cerebral Palsy
NCT06840158	Phase 3	COMPLETED	Double-blind Comparative Randomized Multicenter
NCT07524972	Phase 3	RECRUITING	Antenatal Magnesium Sulphate in High-Risk Preterm Patients
NCT07672158	Phase 3	NOT_YET_RECRUITING	Tranexamic Acid to Reduce Blood Loss After Varus Derotation Osteotomy
NCT00060957	Phase 2	COMPLETED	Botulinum Toxin (BOTOX) for Cerebral Palsy
NCT00061139	Phase 2	UNKNOWN	Constraint-Based Therapy to Improve Motor Function in Children With Cerebral Palsy
NCT00114075	Phase 2	COMPLETED	Effects of Walking Analysis on Surgical Outcomes
NCT00221247	Phase 2	COMPLETED	Acupuncture as Complementary Therapy for Cerebral Palsy
NCT00221611	Phase 2	COMPLETED	Intrathecal Administration of Baclofen (ITB) to Cerebral Palsy Patients With Therapy-Resistant Spasticity
NCT00295295	Phase 2	COMPLETED	Vibration Intervention to Improve Bone and Muscle in Children With Cerebral Palsy
NCT00413946	Phase 2	COMPLETED	Does Erythropoietin Improve Outcome in Very Preterm Infants?
NCT00455637	Phase 2	TERMINATED	Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
NCT00467207	Phase 2	COMPLETED	Intensive Strength Training in Children With Cerebral Palsy - Effect on Hand Function
NCT01028833	Phase 2	COMPLETED	Effects of Power Mobility on Young Children With Severe Motor Impairments
NCT01115998	Phase 2	COMPLETED	Effect of Power Wheelchairs on the Development and Function of Young Children With Severe Physical Disabilities
NCT01147653	Phase 2	COMPLETED	A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for KDM7A across ~30M SureChEMBL compounds — explore on Sugi Predict.